FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:966-969 April 1, 1993 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Dr. Pfeffer and the investigators of the Survival and Ventricular Enlargement (SAVE) study recently (Sept. 3 issue)¹ presented the results of a carefully designed clinical trial suggesting that long-term treatment with the angiotensin-converting-enzyme (ACE) inhibitor captopril can improve survival and reduce cardiovascular morbidity in asymptomatic patients with left ventricular dysfunction after myocardial infarction. However, the authors fail to address the striking discrepancy between women and men in the benefit of ACE inhibition.

As shown in Table 3 of the article, the risk reduction for one of the major end points, death from all causes, was only 2 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Lonn, E., Roccaforte, R., Yi, Q., Dagenais, G., Sleight, P., Bosch, J., Suhan, P., Micks, M., Probstfield, J., Bernstein, V., Yusuf, S., HOPE Investigators, (2002). Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 40: 693-702 [Abstract] [Full Text]  
• Schunkert, H., Danser, A.H. J., Hense, H.-W., Derkx, F. H.M., Kurzinger, S., Riegger, G. A.J. (1997). Effects of Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women. Circulation 95: 39-45 [Abstract] [Full Text]